CBAK Energy Technology, Inc. — 2019 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2019, with comparisons to 2018; it does not provide standalone fourth-quarter results. CBAK develops, manufactures and sells high-power lithium-ion batteries, principally for UPS, electric vehicles and other applications. Operations are conducted mainly in China. The report, signed May 14, 2020, says filing was delayed because COVID-19 restrictions disrupted operations and financial-statement preparation.
Financial performance and condition
- Revenue: $22.19 million, down 9% from $24.43 million. UPS battery revenue rose 9% to $17.67 million; EV battery revenue fell 45% to $4.51 million. UPS accounted for about 79.6% of revenue.
- Profit and margins: Gross profit was $0.62 million, a 2.8% gross margin, versus a $3.30 million gross loss and negative 13.5% margin in 2018. Operating loss narrowed to $10.09 million from $13.44 million. Net loss widened to $10.85 million from $1.96 million; basic and diluted loss per share was $0.28 versus $0.07.
- Cash flow: Operating activities used $21.22 million, compared with $8.73 million provided in 2018. Investing activities used $2.42 million; financing activities provided $13.55 million. Cash, cash equivalents and restricted cash ended at $7.13 million, including $1.61 million of unrestricted cash and $5.52 million of pledged deposits.
- Liquidity: Current assets were $28.49 million and current liabilities $59.00 million, a $30.51 million working-capital deficiency. The auditor cited this deficit, recurring losses and short-term maturities as raising substantial doubt about the company’s ability to continue as a going concern.
- Debt and obligations: Bank borrowings totaled $26.09 million ($16.57 million current and $9.52 million long-term). Other short-term loans were $7.35 million and notes payable were $2.85 million. Bills payable were $3.92 million. The filing lists $118.20 million of contractual obligations due within one year, including substantial proposed capital injections into subsidiaries; total listed obligations were $128.00 million. It reported $4.7 million of unused committed banking facilities.
- Balance sheet: Total assets were $95.58 million, total liabilities $81.93 million and total equity $13.66 million. Capital expenditures were $2.45 million, down from $7.36 million in 2018.
Material changes versus 2018
- Revenue declined, driven mainly by lower EV battery sales, while UPS sales increased and the product mix shifted further toward UPS.
- Gross results improved to a small profit, but the net loss expanded. The comparison is affected by a 2018 net gain of approximately $12.12 million from transferring patented technology; 2019 other income was $0.62 million.
- Operating cash flow swung from positive $8.73 million to negative $21.22 million, primarily amid settlement of trade accounts and bills payable.
- 2019 included $2.33 million of property, plant and equipment impairment, $0.83 million of inventory write-downs, and $1.05 million of doubtful-account expense.
- Shares issued increased substantially, including debt cancellations exchanged for equity. Issued shares rose from 26.79 million at year-end 2018 to 53.22 million at year-end 2019.
Outlook, risks and unusual items
- Management provided no quantified revenue or earnings guidance. It plans to focus more on cylindrical batteries for UPS, reduce EV-battery production and temporarily reduce EV-related R&D investment. Estimated 2020 capital expenditures were approximately $4.0 million for line renovations, a plant, warehouse and battery-pack lines.
- Management said operations had fully resumed by the report date after COVID-19 disruptions in early 2020, but their duration and financial impact remained uncertain.
- Financing plans rely on renewing bank loans and obtaining additional debt or equity; the filing gives no assurance that funding will be available. Atlas Sciences notes carry 10% interest and 12-month maturities. Several 2019 debt and payable balances were converted to shares, and additional debt-to-equity and note exchanges occurred after year-end.
- Customer concentration is significant: the top five customers represented 77.59% of 2019 revenue. Mainland China accounted for 97.47% of sales. Management also cited supplier dependence, raw-material cost and availability, subsidy reductions, competition and customer payment delays as risks.
- Material weaknesses in financial-reporting controls remained; management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2019. The filing also reports unresolved building ownership certificates for Dalian facilities and multiple legal claims, some involving frozen bank deposits. A Nasdaq notice cited the share price below the $1.00 minimum bid requirement, with an extended cure deadline of November 2, 2020.
Important facts for investors to verify
- Near-term liquidity and refinancing capacity, including maturities, restricted cash, pledged assets and the feasibility of planned financing.
- Progress toward remediating control weaknesses, hiring a permanent CFO, and filing timely and reliable reports.
- Customer and supplier concentration, receivable collections, inventory aging and the sustainability of the UPS-focused product mix and gross margin.
- COVID-19’s effects on orders, production, shipments, costs and cash flow after the filing date.
- Status and potential cash impact of litigation, frozen deposits, Dalian property certificates, and Nasdaq listing compliance.
- Potential dilution from equity awards and debt conversions; reconcile post-year-end share issuances with the reported outstanding share count.